What is he best known for?
The fields of study he is best known for:
His scientific interests lie mostly in Maytansinoid, Biochemistry, Cytotoxic T cell, Molecular biology and Monoclonal antibody.
His study looks at the relationship between Maytansinoid and topics such as In vivo, which overlap with Immunoconjugate and Cell culture.
His work in the fields of Biochemistry, such as Metabolite, intersects with other areas such as Linker, Conjugate and PEG ratio.
His Cytotoxic T cell research incorporates elements of Inhibitor of apoptosis, Viral replication, Human cytomegalovirus and Excipient.
His Molecular biology study incorporates themes from Apoptosis, Programmed cell death, Antigen, Cell biology and Antibody.
He combines subjects such as Immunoglobulin light chain, Peptide sequence, Pharmacology and Binding site with his study of Monoclonal antibody.
His most cited work include:
- Cytotoxic agents comprising maytansinoids and their therapeutic use (886 citations)
- Immunoconjugates containing novel maytansinoids: promising anticancer drugs. (464 citations)
- Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. (455 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Molecular biology, Cytotoxicity, Maytansinoid, Antibody and Cytotoxic T cell.
His Molecular biology study combines topics in areas such as Cell culture, Monoclonal, Gelonin and Mitochondrion, Cell biology.
His Cytotoxicity research is under the purview of Biochemistry.
His Maytansinoid study combines topics from a wide range of disciplines, such as Ovarian cancer, Pharmacology, In vivo and Folate receptor.
Victor S. Goldmacher has researched Antibody in several fields, including Toxicity and Antigen.
His research in Cytotoxic T cell intersects with topics in Cancer cell, Cancer research and Cell killing.
He most often published in these fields:
- Molecular biology (27.97%)
- Cytotoxicity (28.81%)
- Maytansinoid (24.58%)
What were the highlights of his more recent work (between 2010-2019)?
- Cytotoxic T cell (24.58%)
- Maytansinoid (24.58%)
- Cancer research (22.03%)
In recent papers he was focusing on the following fields of study:
Victor S. Goldmacher mainly focuses on Cytotoxic T cell, Maytansinoid, Cancer research, Conjugate and Antibody.
His Cytotoxic T cell study integrates concerns from other disciplines, such as Cancer cell, Pharmacology and Cytotoxicity.
His Maytansinoid research includes elements of Tubulin, Biophysics, Ovarian cancer and Folate receptor.
He has included themes like Leukemia, Multiple myeloma and Antibody-drug conjugate in his Cancer research study.
In his work, Receptor expression is strongly intertwined with Antigen, which is a subfield of Antibody.
His Immunology research integrates issues from Cell culture, Cancer therapy and Molecular biology.
Between 2010 and 2019, his most popular works were:
- SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. (174 citations)
- Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. (152 citations)
- IMGN853, a Folate Receptor-α (FRα)–Targeting Antibody–Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors (82 citations)
In his most recent research, the most cited papers focused on:
His primary areas of study are Cytotoxic T cell, Conjugate, Pharmacology, Leukemia and Cancer research.
Victor S. Goldmacher specializes in Cytotoxic T cell, namely Maytansinoid.
He is conducting research in In vitro, Biochemistry and Cytotoxicity as part of his Maytansinoid study.
His study in Pharmacology is interdisciplinary in nature, drawing from both Chronic lymphocytic leukemia, Monoclonal antibody, Bortezomib and Lymphoma.
His work deals with themes such as Cancer cell, Drug and Antigen, which intersect with Monoclonal antibody.
He works mostly in the field of Cancer research, limiting it down to topics relating to Humanized antibody and, in certain cases, Targeted therapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
